Clinical Pharmacogenomics of Antidepressant Response

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

402 participants

Study Classification

OBSERVATIONAL

Study Start Date

2006-01-31

Study Completion Date

2010-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to understand how genetic polymorphisms influence the efficacy and side effect profiles of Paroxetine and Escitalopram for major depression treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Pharmacogenomics of Antidepressant Response

NCT00269334

Major Depression

UNKNOWN PHASE4

Pharmacodynamics and Pharmacokinetics of Citalopram and Escitalopram

NCT00613470

Depression

COMPLETED PHASE1

A Safety and Efficacy Study of Escitalopram on Acute Treatment of Severe Depression

NCT01814085

Major Depressive Disorder

COMPLETED PHASE4

Serotonin Transporter Genetic Variation and Amygdalar Activation Correlates of Antidepressant Response

NCT00456430

Depression

COMPLETED PHASE4

Development of Pharmacogenomic Method to Predict Antidepressant Responsiveness

NCT00817011

Depression Antidepressant Drug Adverse Reaction

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Despite remarkable progress in recent decades in modern psychopharmacotherapy, patients vary substantially in their response to antidepressants, ranging from total remission to complete treatment failure. Adverse effects, often bothersome and occasionally life-threatening, continue to represent significant challenges to patients and clinicians. Mechanisms responsible for such variability remain poorly understood. In addition, although less appreciated, substantial cross-ethnic variations in psychotropic responses often exist. Recent developments in the field of pharmacogenetics indicate that genetic factors may account for a large part of these differences in response. Specific genetic polymorphisms affecting the function of the serotonin (SERT) system has been postulated to predict the effect of antidepressants. Similarly, genetic mutations have been shown to exert a predominant influence on the expression of a number of drug-metabolizing enzymes, including most of the cytochrome P-450 enzymes that are responsible for the biotransformation of most antidepressants. Polymorphisms of genes controlling these enzymes have been found to be strongly associated with the propensity for various kinds of side effects. Capitalizing on these new developments, the proposed study will examine the predictive value of some of these genetic polymorphisms in 400 patients with DSM-IV major depression prospectively treated with Escitalopram (ECIT) or Paroxetine (PAR). It is postulated that mutations affecting the function of SERT will predict responses to ECIT, polymorphism of CYP2C19 will be associated with the side effect profiles and pharmacokinetics of ECIT.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Depression

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Paroxetine (Seroxat)

Intervention Type DRUG

Escitalopram (Lexapro)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* self-identified as of Taiwanese/Chinese ethnic background, and report that both of their parents and all four or three of their grandparents are members of the same ethnic group;
* HAMD-21 \> 17 plus MDE (i.e., current major depressive episode) based on SCID;
* male or female, who, if of child-bearing potential, agrees to use effective contraception including the regular use of contraceptive pills, intra-uterine devises or abstinence;
* age \>= 18;
* capable of giving informed consent;

Exclusion Criteria

* diagnosis of schizophrenia, schizophreniform disorder, schizoaffective disorder, schizotypal disorder, psychotic depression, bipolar disorders;
* current drug or alcohol abuse or dependence or history of drug or alcohol abuse or dependence within the past 6 months;
* unstable medical or neurological conditions that are likely to interfere with the treatment of depression;
* history of allergy to antidepressants;
* history of seizure disorder;
* pregnancy;
* active suicidal ideation or other safety issues determined by the clinician to not be suitable for inclusion in the study;

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No